TIGIT and neoplasm: Although the anti-TIGIT on both isotypes demonstrated equal binding to mTIGIT and blocking of mCD155, significant in vivo anti-tumor efficacy was observed only with the anti-TIGIT: mIgG2a antibody and not the anti-TIGIT:mIgG1* antibody (Figures 1A,B).